Caricamento...
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
Modulating immune inhibitory pathways has been a major recent breakthrough in cancer treatment. Checkpoint blockade antibodies targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programed cell-death protein 1 (PD-1) have demonstrated acceptable toxicity, promising clinical responses, durable di...
Salvato in:
| Pubblicato in: | J Hematol Oncol |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioMed Central
2016
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4884396/ https://ncbi.nlm.nih.gov/pubmed/27234522 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-016-0277-y |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|